about
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationSystemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationAtrial natriuretic peptide modulates the hyperpolarization-activated current (If) in human atrial myocytesMyopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health ProductsPharmacological perspectives in sarcopenia: a potential role for renin-angiotensin system blockers?Regulation of intracellular Na(+) in health and disease: pathophysiological mechanisms and implications for treatmentDoes aspirin attenuate the beneficial effect of ACE inhibitors in elderly people with heart failure?Different implication of NEDD9 genetic variant in early and late-onset Alzheimer's diseaseConsensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease.
P50
Q24193614-968C68A8-2817-4B43-92F9-60A15B815FCAQ24195003-A68C472E-658B-4ED2-876D-559930992027Q24300068-894BACA0-9199-4FA2-A367-853E39242B21Q24657894-D7FF2476-F563-4385-8B53-691D9227DCEDQ26775758-9D2CE957-085E-490D-B31A-26CF120FDF73Q26863221-0F19D74C-1F96-49CE-89DA-B5CD051C7F6DQ28195308-7C1801EE-1A38-4C45-98F8-015C35E49BBAQ28280937-B208F1A1-894C-4068-B935-CC98C6E02644Q30245434-2359A59C-CE61-4985-A127-4F356F997279
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alessandro Mugelli
@ast
Alessandro Mugelli
@en
Alessandro Mugelli
@es
Alessandro Mugelli
@nl
Alessandro Mugelli
@sl
type
label
Alessandro Mugelli
@ast
Alessandro Mugelli
@en
Alessandro Mugelli
@es
Alessandro Mugelli
@nl
Alessandro Mugelli
@sl
prefLabel
Alessandro Mugelli
@ast
Alessandro Mugelli
@en
Alessandro Mugelli
@es
Alessandro Mugelli
@nl
Alessandro Mugelli
@sl